Prothena: Underrated Player In Alzheimer’s And Parkinson’s Close To Securing First Drug Approval
selvanegra/iStock via Getty Images
Investment Thesis
The FDA’s controversial approval of Biogen’s (BIIB) Alzheimer’s Disease therapy Aduhelm, despite its questionable efficacy profile, has had a transformative effect on the share prices of a number of…
